Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
about
Molecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersBlockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eyeGene transfer using micellar nanovectors inhibits choroidal neovascularization in vivoPegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.Liposomal hypocrellin B as a potential photosensitizer for age-related macular degeneration: pharmacokinetics, photodynamic efficacy, and skin phototoxicity in vivo.Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice.Intraplaque haemorrhages as the trigger of plaque vulnerability.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System.Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases.Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.IL-8-mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation.Age-related macular degeneration: current treatment and future options.Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration.Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).Individual benefits of enoxaparin treatment in branch vein occlusion.Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.
P2860
Q26765458-9282C6F0-D6BD-4421-8C8D-64E866BB4888Q28743307-C15D74A4-DB9B-4F9F-BA82-4BAC6CA684EFQ34097675-914B8AEE-05C6-447F-A07B-3D173CA64685Q34346463-8D1D5CFD-67AD-4722-80F5-27284E336668Q34567356-2427F338-85A8-4FBE-BE21-E1C0E0A381B1Q35582389-A36E375A-B56D-4DA2-B614-9657E8EE251AQ36075546-C0B07D63-8C36-428F-A266-47A6B2383E8DQ36384149-A2C4801C-3207-46E0-B0CE-97A457C5AB24Q36702612-311A4FEF-7AE6-47DE-9688-3CD25D51D8A7Q37852494-CD28FE1F-945A-44F5-A660-48BFDF00EF8AQ38032311-E8DB80F8-0DB2-4F54-BBF1-994AAAB608B9Q38210239-7FB4A8E2-4F39-45CF-8227-FCDEEE389747Q38741548-C3D01D87-DB0B-4DB3-961D-B2FDCBC6119DQ39009713-853ED682-CAE9-413A-8D2A-745F69F3FF3AQ39491363-22F854FD-D740-4B6F-903D-ED8208691655Q39496836-1ECB1FBA-FB21-4CAB-84F3-A3A900BF30E4Q39712906-A3663A51-8A51-455F-8CC1-7518A5FDAF75Q42374470-98597728-5DD5-43CA-A675-A4D027E0B9DFQ47995257-2B4B002D-5FEB-44C9-B8D5-1A90DE139B61Q48206019-5A403859-CB83-41CE-86A8-C2850B9290B7Q50164526-99E3DCD6-98EF-4ED2-AEC6-3AC95C68EF2D
P2860
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@en
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@nl
type
label
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@en
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@nl
prefLabel
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@en
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
@nl
P2093
P50
P1476
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration
@en
P2093
Jesús Egido
José Luis Martín-Ventura
José María Ruiz-Moreno
P304
P356
10.1016/J.SURVOPHTHAL.2009.02.003
P577
2009-05-01T00:00:00Z